Brokers Offer Predictions for ELEV Q2 Earnings

Elevation Oncology, Inc. (NASDAQ:ELEV) – Stock analysts at William Blair issued their Q2 2025 earnings per share (EPS) estimates for Elevation Oncology in a research report issued on Friday, March 7th. William Blair analyst A. Hsieh anticipates that the company will post earnings per share of ($0.21) for the quarter. William Blair has a “Outperform” rating and a $5.00 price objective on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. William Blair also issued estimates for Elevation Oncology’s Q3 2025 earnings at ($0.21) EPS and Q4 2025 earnings at ($0.24) EPS.

Elevation Oncology (NASDAQ:ELEV) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04.

Several other research analysts also recently issued reports on the company. Stephens reaffirmed an “overweight” rating and set a $5.00 price target on shares of Elevation Oncology in a research note on Friday. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Elevation Oncology in a report on Tuesday, January 14th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $7.00 price target on shares of Elevation Oncology in a report on Thursday, December 19th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $6.83.

Elevation Oncology Price Performance

Shares of NASDAQ:ELEV opened at $0.51 on Monday. The firm has a market capitalization of $30.20 million, a price-to-earnings ratio of -0.62 and a beta of 1.37. The company has a debt-to-equity ratio of 0.45, a current ratio of 17.77 and a quick ratio of 17.77. The business’s 50 day simple moving average is $0.64 and its 200-day simple moving average is $0.62. Elevation Oncology has a 12 month low of $0.41 and a 12 month high of $5.83.

Institutional Investors Weigh In On Elevation Oncology

Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC boosted its position in Elevation Oncology by 302.4% during the third quarter. Barclays PLC now owns 72,077 shares of the company’s stock worth $43,000 after acquiring an additional 54,167 shares during the last quarter. SG Americas Securities LLC increased its stake in Elevation Oncology by 33.9% in the fourth quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock valued at $35,000 after purchasing an additional 15,560 shares during the last quarter. Geode Capital Management LLC lifted its position in Elevation Oncology by 7.6% during the third quarter. Geode Capital Management LLC now owns 1,110,085 shares of the company’s stock worth $666,000 after buying an additional 78,509 shares during the period. JPMorgan Chase & Co. boosted its stake in Elevation Oncology by 175.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 61,334 shares of the company’s stock worth $37,000 after buying an additional 39,101 shares during the last quarter. Finally, State Street Corp grew its holdings in Elevation Oncology by 13.5% in the 3rd quarter. State Street Corp now owns 1,018,026 shares of the company’s stock valued at $611,000 after buying an additional 120,993 shares during the period. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.